Literature DB >> 7475657

Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery.

S J Pocock1, R A Henderson, A F Rickards, J R Hampton, S B King, C W Hamm, J Puel, W Hueb, J J Goy, A Rodriguez.   

Abstract

A patient with severe angina will often be eligible for either angioplasty (PTCA) or bypass surgery (CABG). Results from eight published randomised trials have been combined in a collaborative meta-analysis of 3371 patients (1661 CABG, 1710 PTCA) with a mean follow-up of 2.7 years. The total deaths in the CABG and PTCA groups were 73 and 79, respectively, with a relative risk (RR) of 1.08 (95% CI 0.79-1.50). The combined endpoint of cardiac death and non-fatal myocardial infarction occurred in 169 PTCA patients and 154 CABG patients (RR 1.10 [0.89-1.37]). Amongst patients randomised to PTCA 17.8% required additional CABG within a year, while in subsequent years the need for additional CABG was around 2% per annum. The rate of additional non-randomised interventions (PTCA and/or CABG) in the first year of follow-up was 33.7% and 3.3% in patients randomised to PTCA and CABG, respectively. The prevalence of angina after one year was considerably higher in the PTCA group (RR 1.56 [1.30-1.88]) but at 3 years this difference had attenuated (RR 1.22 [0.99-1.54]). Overall there was substantial similarity in outcome across the trials. Separate analyses for the 732 single-vessel and 2639 multivessel disease patients were largely compatible, though the rates of mortality, additional intervention, and prevalent angina were slightly lower in single vessel disease. The combined evidence comparing PTCA with CABG shows no difference in prognosis between these two initial revascularisation strategies. However, the treatments differ markedly in the subsequent requirement for additional revascularisation procedures and in the relief of angina. These results will influence the choice of revascularisation procedure in future patients with angina.

Entities:  

Mesh:

Year:  1995        PMID: 7475657     DOI: 10.1016/s0140-6736(95)92897-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

Review 1.  Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit.

Authors: 
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 2.  Intervention in coronary artery disease.

Authors:  S Windecker; B Meier
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 3.  Revascularization strategies in patients with diabetes: evolving concepts.

Authors:  J J Brennan; H S Cabin
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

4.  Investigation and management of stable angina: revised guidelines 1998. Joint Working Party of the British Cardiac Society and Royal College of Physicians of London.

Authors:  D de Bono
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

Review 5.  Fortnightly review: Intracoronary stents.

Authors:  M M Gandhi; K D Dawkins
Journal:  BMJ       Date:  1999-03-06

Review 6.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

7.  Observational research in the evidence based environment: eclipsed by the randomised controlled trial?

Authors:  R H Stables
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

Review 8.  Role of stenting in coronary revascularisation.

Authors:  A H Gershlick
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

9.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

10.  Ischemic Heart Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.